Ameriprise’s Sinovac Biotech, Ltd SVA Stock Holding History

Ameriprise’s Portfolio SVA Stock Details SVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-200	Closed	-$1K	–	5911
2013 Q2	$1K	Buy	+200	New	+$744	﹤0.01%	5479

Other funds holding SVA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

PRCM

Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ameriprise's SVA Position: Q3 2013 in Review

Ameriprise sold out of Sinovac Biotech, Ltd (SVA) in Q3 2013, closing a stake of 200 shares — an estimated $1K sold.

Ameriprise first reported a position in SVA in Q2 2013 and held it in 1 quarter. The position peaked at $1K in Q2 2013. 35 funds tracked by Wall St. Rank hold SVA as of Q3 2013.

Ameriprise reported no remaining Sinovac Biotech, Ltd position as of Q3 2013 after selling out during the quarter.
Ameriprise sold 200 Sinovac Biotech, Ltd shares in Q3 2013, an estimated $1K.
Ameriprise first reported a position in Sinovac Biotech, Ltd in Q2 2013 and held it in 1 quarter.
Ameriprise's Sinovac Biotech, Ltd position peaked at $1K in Q2 2013.
35 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2013.

Based on Ameriprise's 13F filing for Q3 2013, filed 14 Nov 2013.